Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma

Diagnosis and Management of Multiple Myeloma

(2022) Andrew J. Cowan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

What Is Multiple Myeloma?

(2022) Juliet Silberstein et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Intracellular localization of the proteasome in response to stress conditions

(2022) Cordula Enenkel et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma

(2022) Alexander Vdovin et al.   Nature Communications

Lamin B1 sequesters 53BP1 to control its recruitment to DNA damage

(2021) Laure Etourneaud et al.   Science Advances

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma

(2020) Lijie Xing et al.   LEUKEMIA

Progress in Understanding the Molecular Mechanisms Underlying the Antitumour Effects of Ivermectin

(2020) Jian Liu et al.   Drug Design Development and Therapy

A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib

(2020) Gege Chen et al.   CANCER LETTERS

Genome instability in multiple myeloma

(2020) Carl Jannes Neuse et al.   LEUKEMIA

Ivermectin, a potential anticancer drug derived from an antiparasitic drug

(2020) Mingyang Tang et al.   PHARMACOLOGICAL RESEARCH

Ivermectin: An Anthelmintic, an Insecticide, and Much More

(2020) Richard J. Martin et al.   TRENDS IN PARASITOLOGY

Targeting KPNB1 overcomes TRAIL resistance by regulating DR5, Mcl-1 and FLIP in glioblastoma cells

(2019) Zhi-Chuan Zhu et al.   Cell Death & Disease

Multiple myeloma: Every year a new standard?

(2019) S. Vincent Rajkumar   HEMATOLOGICAL ONCOLOGY

Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway

(2019) Lu Jiang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Lamin B1 in cancer and aging

(2019) Boyan K. Garvalov et al.   Aging-US

Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway

(2018) Ping Zhang et al.   CELL PROLIFERATION

Ivermectin – Old Drug, New Tricks?

(2017) Roz Laing et al.   TRENDS IN PARASITOLOGY

FCN2 inhibits epithelial–mesenchymal transition-induced metastasis of hepatocellular carcinoma via TGF-β/Smad signaling

(2016) Guangchao Yang et al.   CANCER LETTERS

Avermectin Confers Its Cytotoxic Effects by Inducing DNA Damage and Mitochondria-Associated Apoptosis

(2016) Yang Zhang et al.   JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

A Second WNT for Old Drugs: Drug Repositioning against WNT-Dependent Cancers

(2016) Kamal Ahmed et al.   Cancers

Proteasome assembly

(2014) Zhu Chao Gu et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Proteasome dynamics

(2013) Cordula Enenkel   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Proteasome inhibition induces DNA damage and reorganizes nuclear architecture and protein synthesis machinery in sensory ganglion neurons

(2013) Ana Palanca et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus

(2012) Kylie M. Wagstaff et al.   BIOCHEMICAL JOURNAL

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors

(2011) P. Neri et al.   BLOOD

The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells

(2010) S. Sharmeen et al.   BLOOD

The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 1: post-translational regulation

(2009) Panagiotis J. Vlachostergios et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation

(2009) Panagiotis J. Vlachostergios et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE